Robert A. Volkmann

Biography

Bob is a distinguished medicinal chemist who was actively involved in the areas of process chemistry, immunology, infectious disease, diabetes, neuroscience, natural product isolation and in developing new technologies to impact drug discovery while working at Pfizer. He has over 100 patents and publications and has given numerous scientific presentations over the years. While at Pfizer, his laboratory prepared Englitazone, a PPAR gamma agonist for the treatment of diabetes and Sulopenem, a potent broad spectrum penem antibacterial. In addition, his laboratory was involved in the discovery of a series of nNOS inhibitors for the treatment of stroke, novel glutamate antagonists, novel p-type calcium channel antagonists, novel neurotransmitter release enhancers and 5HT2A/SRI agents for the treatment of depression. He has a long-standing interest in neuroscience and in the development of systems-based approaches for complex biological analyses. Bob is an ACS Fellow and was a previous Chair-Elect of the ACS Organic Division.

Research Interest

nNOS inhibitors, Englitazone, a PPAR gamma agonist for the treatment of diabetes and Sulopenem,neuroscience